• OPEN AN ACCOUNT
Indian Indices
Nifty
25,330.25 91.15
(0.36%)
Sensex
83,013.96 320.25
( 0.39%)
Bank Nifty
55,493.30 345.70
( 0.63%)
Nifty IT
36,447.15 235.00
( 0.65%)
Global Indices
Nasdaq
46,015.42 236.51
(0.52%)
Dow Jones
6,617.88 9.88
(-0.15%)
Hang Seng
45,342.39 552.01
(1.23%)
Nikkei 225
9,208.37 12.71
(0.14%)
Forex
USD-INR
88.02 0.00
(0.00%)
EUR-INR
104.02 0.00
(0.00%)
GBP-INR
120.02 0.00
(0.00%)
JPY-INR
0.60 0.00
(0.00%)

EQUITY - MARKET SCREENER

Divis Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
532488
INE361B01024
561.0868795
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DIVISLAB
68.76
160625.75
EPS(TTM)
Face Value()
Div & Yield %
88
2
0.49
 

divis laboratories ltd
Divis Lab slides after Q1 PAT falls 18% QoQ to Rs 545 cr
Aug 06,2025
Revenue from operations also declined 6.79% quarter on quarter (QoQ) to Rs 2,410 crore for the quarter ended 30 June 2025

On a year-on-year (YoY) basis, the company’s net profit rose 26.74%, while revenue increased 13.78%, indicating continued growth over the previous year despite the sequential decline.

Profit before tax for the quarter stood at Rs 733 crore, down 15.16% QoQ but up 21.35% YoY.

The company reported a forex gain of Rs 39 crore during the quarter, compared to a forex loss of Rs 1 crore in the corresponding quarter of the previous financial year.

On a standalone basis, the company’s net profit surged 29.53% to Rs 557 crore on a 14.25% rise in revenue to Rs 2,357 crore in Q1 FY26 over Q1 FY25.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.